Escala Medical

Escala Medical is developing the first repair device for the treatment of pelvic organ prolapse (POP) based on a nonsurgical, incision-free, mesh-free repair approach.

Escala’s novel system presents a long-overdue repair option for women with mild to moderate POP. Escala’s approach mirrors a gold standard surgery-based repair to fixate the vaginal apex to the sacrospinous ligament (SSL) in a safe, quick outpatient procedure.

• Incision- and mesh-free
• Safe, quick, and easy to perform fixation
• Restores anatomy and preserves pelvic organ functionality
• Outpatient (ambulatory) or office-based procedure with minimal hospital stay
• Reduced complications and minimal patient discomfort

IP

• 1 US patent granted
• 2 National phase (US, Brazil, EU, China, India, Australia, Japan)
• PCT international patent application (filed in the United States)

• September 2019: Beginning to recruit patients for a clinical study that will take place at Hadassah Hospital in Jerusalem

In the Media

• 2019: The Journal of Minimally Invasive Gynecology, animal/cadaver study results using Escala-developed Apyx
• 2019: Calcalist (Hebrew): For entrepreneurial women, it’s easier to raise money — they paved the way
• 2019: Interview on A Healthy Morning (Israeli TV program)
• 2018: Start-Up Stadium (Hebrew)
• 2017: Hadassah Magazine (2017): Can stem cells fix a weakened pelvic floor?
• 2016: Israel21c: First-ever incision-free fix for pelvic organ prolapse

POP is a clinical condition that affects millions of women worldwide. Associated with physical, psychological, and sexual problems, POP has a significant impact on quality of life. Treatment options are limited.

• Supportive devices (pessaries) provide transient symptom relief but may cause significant complications and discomfort.
• Invasive repair surgeries (abdominal and transvaginal approaches) involve hospitalization and cause early- and late-stage complications

Surgeons specializing in POP repair are in immediate need of minimally invasive solutions that provide permanent relief of symptoms for the large number of women who are reluctant to use pessaries or undergo surgery.

More than 3.3 million women in the United States are diagnosed with POP. By 2050, it is estimated that the incidence of women with POP will increase by 46%. About 20% undergo surgery for POP (or UI) before the age of 80. Approximately 400,000 surgical repair procedures for POP are performed annually at an estimated direct cost of $1.4 billion.

Escala Medical believes its repair system will increase market potential as a solution for women who may be poor surgical candidates or are reluctant to undergo surgery. The Company estimates the U.S. market opportunity to exceed $600 million.